KN057 / Alphamab, Grand Shuyang Life Sciences - LARVOL DELTA

An Ex Vivo Pharmacodynamic Study of KN057, a Tissue Factor Pathway Inhibitor Neutralizing Antibody, in Plasma Samples From Patients With Haemophilia or VWD3. (PubMed, Haemophilia) - "KN057 exhibited a consistent ex vivo pharmacodynamic profile, including both the response trend and effective concentration range, across plasma samples from patients with HA or HB, irrespective of inhibitor status. Furthermore, its pharmacodynamic activity in plasma from patients with VWD3 was comparable to that observed in haemophilia plasma."

Journal • PK/PD data • Preclinical • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

Safety of KN057 Prophylaxis in Patients With Haemophilia A or B (clinicaltrials.gov) - P3 | N=70 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd.

New P3 trial • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors (clinicaltrials.gov) - P3 | N=53 | Active, not recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B Without Inhibitors (clinicaltrials.gov) - P3 | N=125 | Active, not recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Completed | Sponsor: Suzhou Alphamab Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Sep 2024 ➔ Jan 2024

Trial completion • Trial completion date • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

KN057 Multiple Dose Study in Patients with Hemophilia a or Hemophilia B with or Without Inhibitors (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Suzhou Alphamab Co., Ltd.

New P2 trial • Hematological Disorders • Hemophilia • Hemophilia A • Hemophilia B • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Trial completion date: Jun 2024 ➔ Sep 2024

Trial completion date • Hematological Disorders • Hemophilia • Rare Diseases

Efficacy and Safety of KN057 Prophylaxis in Patients With Haemophilia A or B With Inhibitors (clinicaltrials.gov) - P3 | N=51 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd.

New P3 trial • Hematological Disorders • Hemophilia • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Trial completion date: Dec 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Jan 2024

Trial completion date • Trial primary completion date • Hematological Disorders • Hemophilia • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Recruiting | Sponsor: Suzhou Alphamab Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Hematological Disorders • Hemophilia • Rare Diseases

KN057 Multiple Dose Study in Moderately Severe to Severe Hemophilia (clinicaltrials.gov) - P2 | N=24 | Not yet recruiting | Sponsor: Suzhou Alphamab Co., Ltd.

New P2 trial • Hematological Disorders • Hemophilia • Rare Diseases